Share on StockTwits
 

United Therapeutics Corp. (NASDAQ:UTHR) EVP Paul A. Mahon unloaded 6,000 shares of the stock on the open market in a transaction dated Thursday, February 6th. The shares were sold at an average price of $97.41, for a total transaction of $584,460.00. Following the sale, the executive vice president now directly owns 34,490 shares in the company, valued at approximately $3,359,671. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded up 1.22% on Thursday, hitting $97.21. The stock had a trading volume of 664,458 shares. United Therapeutics Corp. has a one year low of $52.98 and a one year high of $116.65. The stock has a 50-day moving average of $107.3 and a 200-day moving average of $87.66. The company has a market cap of $4.882 billion and a price-to-earnings ratio of 17.45. United Therapeutics Corp. also was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 6,166,867 shares, a decline of 26.3% from the December 31st total of 7,791,595 shares. Approximately 13.4% of the shares of the stock are sold short. Based on an average trading volume of 726,990 shares, the days-to-cover ratio is currently 8.5 days.

A number of analysts have recently weighed in on UTHR shares. Analysts at Zacks upgraded shares of United Therapeutics Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, January 24th. They now have a $135.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Finally, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. United Therapeutics Corp. presently has a consensus rating of “Hold” and a consensus price target of $91.07.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.